留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

两性霉素B联合用药的研究进展

赵柳娅,  曹颖瑛,  姜远英

downloadPDF
文章导航 > 药学实践与服务  > 2014 >  32(1): 1-4,8
赵柳娅, 曹颖瑛, 姜远英. 两性霉素B联合用药的研究进展[J]. 药学实践与服务, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
引用本文: 赵柳娅, 曹颖瑛, 姜远英. 两性霉素B联合用药的研究进展[J]. 药学实践与服务, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
shu
ZHAO Liuya, CAO Yingying, JIANG Yuanying. Research progress in the combined use of amphotericin B[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
Citation: ZHAO Liuya, CAO Yingying, JIANG Yuanying. Research progress in the combined use of amphotericin B[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
shu

两性霉素B联合用药的研究进展

doi: 10.3969/j.issn.1006-0111.2014.01.001

  • 第二军医大学药学院新药研究中心, 上海 200433

Research progress in the combined use of amphotericin B

  • The Center of New Drug Development, Second Military Medical University, Shanghai 200433, China

  • 摘要: 两性霉素B(amphotericin B,AmB)属于多烯类抗真菌药物,因其耐药率低、抗菌谱广,被称为治疗深部真菌感染的"金标准",但是严重的毒副作用(尤其是肾毒性)大大限制了AmB在临床上的应用。在目前高效、低毒的抗真菌药物较少的情况下,联合使用不同作用机制的抗真菌药物,使其发挥协同作用,缩短疗程、减少药物毒副作用、扩大药物抗菌谱、避免耐药性的出现,是当前深部真菌感染治疗研究领域的一个重要研究方向。本文对AmB与不同种类抗真菌药物联合使用的研究进展作一综述。
    Abstract: Objective Amphotericin B (AmB) was a polyene antifungal agent. Because of its lowest resistance rate and broad antibiotic spectrum, AmB was considered as a "gold standard" for the treatment of deep fungal infections. However, the occurrence of toxicity and serious side effects, especially renal toxicity, greatly limited the application of AmB in clinical antifungal therapy. Due to the lack of antifungal with high efficiency and low toxicity, the combination of antifungal agents with different mechanisms of action was a promising research direction. The advantage of the combinations was the course of treatment shortened, drug side effects reduced, the antibacterial spectrum expanded, and drug resistance avoided. The research progress in the combined use of AmB with different types of antifungal compounds were introduced in this article.
  • [1] Montoya JG,Rosso F. Is combination therapy indicated for invasive fungal infections?Yes and no[J].Curr Opin Infect Dis,2006,19(4):371-379.
    [2] Nivoix Y,Zamfir A,Lutun P,et al,Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections[J].J Infect,2006,52(1):67-74.
    [3] Kontoyiannis DP,Lewis RE.Combination chemotherapy for invasive fungal infections:what laboratory and clinical studies tell us so far[J].Drug Resist Updat,2003,6(1):257-269.
    [4] Mukherjee PK,Sheehan DJ,Hitchcock CA,et al.Combination treatment of invasive fungal infections[J].Clin Microbiol Rev,2005,18(1):163-194.
    [5] Chamilos G,Kontoyiannis DP.The rationale of combination antifungal therapy in severely immuncompromised patients:empiricism versus evidence-based medicine[J].Curr Opin Infect Dis,2006,19(4):380-385.
    [6] Marr KA,Boeckh M,Carter RA,et al.Combination antifungal therapy for invasive aspergillosis[J].Clin Infect Dis,2004,39(6):797-802.
    [7] Matsuoka S, Murata M. Cholesterol markedly reduces ion permeability induced by membrane-bound amphotericin B[J]. Biochim Biophys Acta, 2002,1564(2):429-434.
    [8] Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity:a review[J]. J Chemother, 2000,12(6):463-470.
    [9] Mayer J, Doubek M, Doubek J, et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures:animal experiments and clinical study[J]. J Infect Dis 2002,186(3):379-388.
    [10] Louie A, Kaw P, Banerjee P,et al. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis[J].Antimicrob Agents Chemother, 2001, 45(2):485-494.
    [11] Samaranayake YH, Samaranayake LP, Yeung KW. Evaluation of polyene-azole antagonism in liquid cultures of Candida albicans using an automated turbidometric method[J].Chemotherapy, 2001, 47(4):279-291.
    [12] Barchiesi F, Schimizzi AM, Caselli F,et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans[J].Antimicrob Agents Chemother, 2000, 44(9):2435-2441.
    [13] Popp AI, White MH, Quadri T,et al. Amphotericin B with and without itraconazole for invasive aspergillosis. A three-year retrospective study[J].Int J Infect Dis, 1999, 3(3):157-160.
    [14] Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species[J].MedMycol, 2001, 39(1):91-95.
    [15] Rodero L, Cordoba S, Cahn, P,et al. In vitro susceptibility studies of Cryptococcus Neoformans isolated from patients with no clinical response to amphotericin B therapy[J].J Antimicrob Chemother,2000, 45(2):239-242.
    [16] Perfect JR, Dismukes WE, Dromer F,et al. Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2010,50(3):291-322.
    [17] Sevtap Arikan, Mario Lozano-Chiu,Victor Paetznick, et al.In vitro synergy of caspofungin and amphotericin B Against Aspergillus and Fusarium spp[J].Antimicrob Agents Chemother,2002, 46(1):245-247.
    [18] Jon AO, Adler-Moore JP, Smith PJ, et al. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin[J]. Antimicrob Agents Chemother,2005, 49 (12):4895-4902.
    [19] Francesco B,Elisabetta S,Serena T, et al.Caspofungin in combination with amphotericin B against Candida parapsilosis[J]. Antimicrob Agents Chemoth, 2007, 51(3):941-945.
    [20] Ogita A, Hirooka K, Yamamoto Y, et al. Synergistic fungicidal activity of Cu2+ and allicin, an allyl sulfur compound from garlic, and its relation to the role of alkyl hydroperoxide reductase 1 as a cell surface defense in Saccharomyces cerevisiae[J]. Toxicology,2005,215(3):205-13.
    [21] Xu Y, Wang Y, Yan L, et al. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans:endogenous ROS augmentation[J]. J Proteome Res,2009,8(11):5296-304.
    [22] An M, Shen H, Cao Y, et al.Allicin enhances the oxidative damage effect of amphotericin B against Candida albicans[J]. Int J Antimicrob Agents. 2009; 33(3):258-63.
    [23] Cao YY,Dai BD, Wang Y, et al.In vitro activity of baicalein against Candida albicans biofilms[J]. Int J Antimicrob Agents, 2008,32:73-77.
    [24] Huang S, Cao YY, Dai BD, et al. In vitro synergism of fluconazole and baicalein against clinical isolates of Candida albicans resistant to fluconazole.Biol Pharm Bull, 2011,31:2234-2236.
    [25] Fu ZJ, Lu H,Zhu ZY, et al.Combination of baicalein and amphotericin B accelerates Candida albicans apoptosis[J].Biol Pharm Bull,2011,34(2):214-218.
    [26] Phillips AJ, Sudbery I, Ramsdale M.Apoptosis induced by environmental stresses and amphotericin B in Candida albicans[J]. Proc Natl Acad Sci,2003,100:14327-14332.
    [27] Phillips AJ, Crowe JD, Ramsdale M.Ras pathway signaling accelerates programmed cell death in the pathogenic fungus Candida albicans[J].Proc Natl Acad Sci,2006,103:726-731.
    [28] Cao YY,HuangS, Dai BD, et al.Candida albicans cells lacking CaMCA1-encoded metacaspase show resistance to oxidative stress-induced death and change in energy metabolism[J].Fungal Genet Biol,2009,46:183-189.
    [29] Clancy CJ, Wingard JR, Hong-Nguyen M. Subcutaneous phaeohyphomycosis in transplant recipients:review of the literature and demonstration of invitro synergy between antifungal agents[J].Med Mycol, 2000, 38(2):169-175.
    [30] Ellis M, Watson R, McNabb A,et al. Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery[J].J Med Microbiol,2002, 51(1):70-75.
  • [1] 孙雨菡, 许子艺, 廖峻, 张翮, 樊莉, 鲁莹.  HPLC法同时测定盐酸阿霉素与氯尼达明的含量 . 药学实践与服务, 2024, 42(3): 127-130. doi: 10.12206/j.issn.2097-2024.202306043
    [2] 万立志, 王境焓, 吴春蓉, 李玲.  基于代谢组学技术的烟酰胺协同两性霉素B抑制白念珠菌的作用机制研究 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202307034
    [3] 范加腾, 陆峰, 许激扬.  基于D-SERS法表征两性霉素B对白色念珠菌抑制作用的研究 . 药学实践与服务, 2019, 37(2): 156-161,169. doi: 10.3969/j.issn.1006-0111.2019.02.011
    [4] 白向荣, 程红勤, 张雁, 金颖.  两性霉素B膀胱冲洗治疗真菌尿的荟萃分析 . 药学实践与服务, 2018, 36(4): 379-384. doi: 10.3969/j.issn.1006-0111.2018.04.021
    [5] 马宗强, 安洪亮.  门诊口服抗高血压药物的调查分析 . 药学实践与服务, 2016, 34(2): 188-190,192. doi: 10.3969/j.issn.1006-0111.2016.02.024
    [6] 赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕.  神经病理性疼痛的药物治疗进展 . 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
    [7] 刘丽娜, 刘晓东, 肇丽梅.  1例糖尿病合并侵袭性肺曲霉菌感染患者的药学监护 . 药学实践与服务, 2014, 32(5): 389-392. doi: 10.3969/j.issn.1006-0111.2014.05.022
    [8] 郭凯欣, 石宽, 闻俊, 周婷婷, 范国荣.  唑类抗真菌药物手性分离及药代动力学研究进展 . 药学实践与服务, 2012, 30(6): 418-421. doi: 10.3969/j.issn.1006-0111.2012.06.006
    [9] 向丽, 姜鹏, 胡耀华, 王淑萍, 张卫东, 柳润辉.  "Polypill"的发展及前景 . 药学实践与服务, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
    [10] 陈开宇, 江丽萍, 陈盛新.  慢性阻塞性肺疾病的药物治疗进展 . 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
    [11] 赵民生, 曹秀虹.  利尿剂在治疗心血管疾病时的不良反应及处理 . 药学实践与服务, 2006, (6): 353-354.
    [12] 胡宏岗, 赵庆杰, 张俊, 吴秋业, 刘超美, 徐建明.  抗真菌药物作用靶位的研究进展 . 药学实践与服务, 2005, (2): 65-71.
    [13] 唐斌, 何佩珍, 徐帆, 尚北城.  黄连素的联合用药 . 药学实践与服务, 2005, (5): 278-281.
    [14] 尹玉琴, 王根春, 李崇映, 李春东, 徐贵丽.  5种抗真菌药物的体外敏感性试验 . 药学实践与服务, 2004, (2): 79-80.
    [15] 曹琴, 范伟, 王凯伟.  抗真菌药物的研究进展和临床应用 . 药学实践与服务, 2003, (4): 225-228.
    [16] 张生大.  双嘧达莫与其它药物合用的新用途 . 药学实践与服务, 2001, (1): 13-13.
    [17] 罗东, 马文秀, 代青, 刘松青.  HPLC法测定两性霉素B含量 . 药学实践与服务, 1998, (3): 166-168.
    [18] 王晓明, 张紫洞.  两性霉素B溶液治疗鹅口疮 . 药学实践与服务, 1989, (3): 56-56.
    [19] 丁祯禄, 冯仰华.  两性霉素B和多粘菌素B相互作用的实验研究 . 药学实践与服务, 1985, (2): 79-79.
    [20] 李国秀, 于文英.  联合用药处方调查及分析 . 药学实践与服务, 1984, (3): 28-31.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2080
  • HTML全文浏览量:  271
  • PDF下载量:  126
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-03-12
  • 修回日期:  2013-09-02

两性霉素B联合用药的研究进展

doi: 10.3969/j.issn.1006-0111.2014.01.001
  • 第二军医大学药学院新药研究中心, 上海 200433
  • 收稿日期: 2013-03-12
  • 修回日期: 2013-09-02

摘要: 两性霉素B(amphotericin B,AmB)属于多烯类抗真菌药物,因其耐药率低、抗菌谱广,被称为治疗深部真菌感染的"金标准",但是严重的毒副作用(尤其是肾毒性)大大限制了AmB在临床上的应用。在目前高效、低毒的抗真菌药物较少的情况下,联合使用不同作用机制的抗真菌药物,使其发挥协同作用,缩短疗程、减少药物毒副作用、扩大药物抗菌谱、避免耐药性的出现,是当前深部真菌感染治疗研究领域的一个重要研究方向。本文对AmB与不同种类抗真菌药物联合使用的研究进展作一综述。

English Abstract

赵柳娅, 曹颖瑛, 姜远英. 两性霉素B联合用药的研究进展[J]. 药学实践与服务, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
引用本文: 赵柳娅, 曹颖瑛, 姜远英. 两性霉素B联合用药的研究进展[J]. 药学实践与服务, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
shu
ZHAO Liuya, CAO Yingying, JIANG Yuanying. Research progress in the combined use of amphotericin B[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
Citation: ZHAO Liuya, CAO Yingying, JIANG Yuanying. Research progress in the combined use of amphotericin B[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
shu

    全文HTML

参考文献 (30)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计